secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001193125-25-076938
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee
--------------------------------------------------------------------------------

- Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
- Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.
- Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.
- TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.
- Company cites unavailable capital markets as reason to seek a strategic partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/0001193125-25-076938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/d906762d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-076938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer